[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_100":101,"_102":57},"item-original",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":25,"_29":30,"_31":32,"_33":34,"_35":36,"_37":38,"_39":-5,"_38":40,"_41":-5,"_42":-5,"_43":-5,"_44":45,"_46":47,"_48":-5,"_49":50,"_51":52,"_53":54,"_55":36,"_56":57,"_58":-5,"_59":60,"_61":62,"_63":36,"_64":57,"_65":66},"id","cgmgd0uacpvw0ldg90chnkblp","revision",2,"title","At the","originalTitle","summary","reason","source",{"_11":94,"_75":95,"_96":97,"_98":36,"_99":-5},"links",{"_91":92,"_66":93},"publishedAt","2026-04-20T12:02:59.000Z","discoveredAt","2026-10-22T11:08:55.027Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_84":85,"_86":47,"_87":-5,"_88":-5,"_89":90},"insight","digest","conferenceAbstracts","readingMode","full","author","Palleon_Pharma","language","body",{"_79":-5,"_66":80,"_81":82,"_83":57},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_73":74,"_75":76,"_77":-5,"_78":-5},"engagement",{"_67":68,"_69":68,"_70":71,"_72":71},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",4,"likes","replies",0,"reposts","slug","aacr-2026","name","AACR 2026 年会","topic","reading","zh","

At the
@AACR
Annual Meeting, we presented preclinical data on E-688/HLX316, a first-in-class B7-H3 targeted sialidase currently in a Phase 1 clinical trial with our partner
@HenliusBiotech
.

Read more in our latest press release:
https://
bit.ly/3QvC62f

#AACR26 #glycotime

","zhKind","translation","complete","authorName","Palleon Pharma","handle","avatarUrl","quoted","media",[],"aihot","/items/cgmgd0uacpvw0ldg90chnkblp","https://x.com/Palleon_Pharma/status/2046197937307345090","aacr26-floor","AACR 2026 现场信号","kind","x_search","firstParty","iconUrl","changelogVersion","2026-10-23T01:25","enEditionEnabled"]